JPMorgan raised the firm’s price target on Johnson & Johnson to $195 from $185 and keeps a Neutral rating on the shares. The firm left its large cap biopharma estimates largely unchanged but adjusted price targets on a move to December 2026 from December 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots
- Kenvue Stock (KVUE) Up after CEO Met Health Secretary to Kick Tylenol Off Autism Report
- Protagonist Therapeutics initiated with an Outperform at Leerink
- Protagonist Therapeutics announces icotrokinra application submitted to EMA
- Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads